LINDSAY MOFFETT: Open Payments
NPI 1851030464 · STAUNTON, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$577 in 10 payments from 8 companies in 2025. Trend: 2023 $426 · 2024 $610 · 2025 $577
Food & beverage: $577
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $130 |
| Neurocrine BioSciences, Inc. | 2 | $129 |
| Otsuka America Pharmaceutical, Inc. | 2 | $124 |
| Vanda Pharmaceuticals Inc. | 1 | $103 |
| Janssen Pharmaceuticals, Inc | 1 | $25 |
| Lundbeck LLC | 1 | $24 |
| E.R. Squibb & Sons, L.L.C. | 1 | $22 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $21 |
Products named: CAPLYTA, INGREZZA, REXULTI, FANAPT, INVEGA SUSTENNA, ABILIFY MAINTENA, COBENFY.
Industry payments across VA — which companies pay providers there.
